

## Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

Héctor Cisneros Pérez<sup>1</sup>, Mario Hernandez Mancillas<sup>1</sup>, Marina Gallegos Colón<sup>1</sup>, Luis Jorge Caldera Sanchez<sup>1</sup>, Omar Guadalupe Dorado Hernandez<sup>2</sup>

<sup>1</sup>Hospital del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Zacatecas. Zacatecas, Zacatecas, Mexico.

<sup>2</sup>Hospital General de Zacatecas "Luz González Cosío". Secretaria de salud. Zacatecas, Zacatecas, México.

### ABSTRACT

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) is a complex clinical entity characterized by the onset of autoimmune or inflammatory responses following exposure to adjuvants, substances that enhance immune responses. One of the most studied triggers of ASIA is breast implants, which are commonly composed of silicone. While breast implants are generally considered safe, a subset of patients may develop systemic symptoms collectively termed as "Breast Implant Illness" (BII), now recognized within the broader spectrum of ASIA. This review provides a thorough analysis of the pathophysiology, clinical presentation, diagnostic challenges, and management options for ASIA associated with breast implants. We aim to elucidate the underlying mechanisms of immune dysregulation and inflammatory responses induced by silicone and explore the latest evidence-based therapeutic approaches, including explantation surgery and immunosuppressive therapies. Our review underscores the need for heightened clinical awareness and further research into ASIA, as early recognition and intervention can significantly improve patient outcomes.

**KEYWORDS:** ASIA syndrome, Breast implant illness, Autoimmune diseases, Silicone adjuvants, Inflammatory response, Explantation, Autoimmunity, Breast implants, Adjuvant-induced disease, Silicone-induced autoimmunity.

### ARTICLE DETAILS

**Published On:**  
**23 October 2024**

**Available on:**  
**<https://ijmscr.org/>**

### INTRODUCTION

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) represents a novel category of disorders that arise in response to environmental exposure to substances that act as immune adjuvants. First introduced by Shoenfeld in 2011, ASIA encompasses a wide range of clinical conditions, including Gulf War syndrome, macrophagic myofasciitis, and siliconosis, all of which share a common pathophysiological mechanism: the activation of immune pathways through adjuvants. Silicone, a material widely used in medical devices such as breast implants, has been implicated as one of the leading causes of ASIA. While breast implants have been extensively used in both reconstructive and cosmetic surgery, concerns have emerged regarding their potential to elicit systemic autoimmune or inflammatory responses in susceptible individuals.<sup>1,2</sup>

Patients with ASIA associated with breast implants commonly present with a constellation of nonspecific symptoms, including fatigue, arthralgia, myalgia, cognitive dysfunction, and chronic pain. These symptoms often overlap with other autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, making diagnosis challenging. Despite the growing number of reported cases and patient advocacy movements, such as those surrounding "Breast Implant Illness," the pathogenesis of ASIA in this context remains poorly understood. Studies suggest that silicone may act as a chronic stimulus to the immune system, triggering an inflammatory cascade that leads to the development of autoimmunity in genetically predisposed individuals.<sup>1,2</sup>

This article aims to explore the clinical features, diagnostic approaches, and therapeutic strategies for ASIA related to breast implants. We will discuss the immunological

# Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

mechanisms underlying this syndrome, as well as the controversial role of silicone in autoimmunity. Furthermore, we will evaluate the evidence supporting various management strategies, particularly explantation surgery, which has been shown to provide symptomatic relief in a significant proportion of patients. Through this review, we hope to contribute to the growing body of literature on ASIA and breast implant-associated autoimmune disorders, highlighting the need for further research into this emerging clinical entity.

## Epidemiology

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), particularly in the context of breast implants, is an emerging entity within the broader field of autoimmune and inflammatory diseases. The true prevalence and incidence of ASIA related to breast implants remain largely undetermined, owing to several factors, including underreporting, lack of standardized diagnostic criteria, and overlapping clinical manifestations with other autoimmune diseases. Despite these challenges, the increasing awareness and recognition of Breast Implant Illness (BII) as a component of ASIA have prompted more epidemiological investigations into the phenomenon.<sup>3,4</sup>

Breast augmentation and reconstruction with silicone implants have become one of the most commonly performed surgical procedures worldwide, with millions of women undergoing implantation. According to data from the American Society of Plastic Surgeons (ASPS), over 300,000 breast augmentations and approximately 100,000 breast reconstructions are performed annually in the United States alone. Silicone implants are the most frequently used devices due to their aesthetic advantages and longer lifespan. Given the widespread use of silicone breast implants, even a small proportion of individuals developing ASIA-related symptoms could represent a significant clinical burden.<sup>4,5</sup>

However, the incidence of ASIA among patients with breast implants remains controversial and difficult to quantify. A large cohort study conducted by the FDA in the early 2000s involving tens of thousands of women with silicone breast implants did not conclusively demonstrate an increased risk of developing systemic autoimmune diseases such as lupus or rheumatoid arthritis compared to the general population. Nevertheless, case reports and small observational studies have since highlighted that certain patients with breast implants do develop systemic autoimmune symptoms consistent with ASIA.<sup>4,5</sup>

Retrospective analyses and patient-reported outcomes suggest that a small but clinically significant subset of individuals with silicone breast implants may develop ASIA-related symptoms. These individuals often present with vague, nonspecific complaints such as chronic fatigue, myalgia, arthralgia, and cognitive dysfunction. A notable finding is that the onset of symptoms can occur months to years after implantation, complicating epidemiological

tracking. Furthermore, these symptoms can mimic those of established autoimmune diseases, leading to diagnostic challenges and potential misclassification in epidemiological studies.<sup>5,6</sup>

The demographic distribution of ASIA related to breast implants indicates a predominance of cases in middle-aged women, reflecting the typical patient population for breast augmentation and reconstruction. Age at onset of symptoms can vary widely, but most women report symptom onset between 30 and 50 years of age. Genetic predisposition has also been postulated as a contributing factor, with certain HLA haplotypes associated with an increased risk of developing autoimmune disorders following exposure to adjuvants. However, large-scale genetic studies specific to ASIA and breast implants are still lacking.<sup>5,6</sup>

Geographically, the epidemiology of ASIA related to breast implants mirrors the global distribution of breast augmentation surgeries, with the highest rates observed in North America, South America, and Europe. The increased prevalence of breast implants in these regions correlates with the higher number of ASIA-related case reports and patient advocacy groups. For instance, in the United States, organizations such as the Breast Implant Illness and Healing support group have raised awareness about the potential link between breast implants and systemic autoimmune symptoms, further driving epidemiological interest in this syndrome.<sup>5,6</sup>

In terms of risk factors, several studies have proposed that individuals with a personal or family history of autoimmune diseases may be at higher risk of developing ASIA after breast implantation. Additionally, the duration of implant exposure and the presence of local inflammatory complications, such as capsular contracture or implant rupture, may also increase susceptibility to ASIA. However, these associations remain speculative, and further epidemiological research is needed to clarify the potential role of these factors in the development of ASIA.<sup>5,6</sup>

Long-term follow-up studies and population-based registries are critical for accurately defining the epidemiology of ASIA in relation to breast implants. Current estimates suggest that between 1% and 10% of women with silicone breast implants may develop symptoms consistent with ASIA, though these figures are subject to significant variability due to differences in study design, patient selection, and diagnostic criteria. The establishment of standardized diagnostic guidelines for ASIA and more robust reporting systems will be essential to improving the accuracy of epidemiological data in the future.<sup>5,6</sup>

The epidemiology of ASIA related to breast implants is still in its infancy, with many unanswered questions regarding its true prevalence, risk factors, and long-term outcomes. While breast implants remain a popular and generally safe option for many women, the recognition of ASIA as a potential complication highlights the importance of further

# Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

epidemiological research to better understand and manage this emerging syndrome. This will require a collaborative effort between plastic surgeons, immunologists, and epidemiologists to ensure that patients are appropriately informed and managed should they develop symptoms suggestive of ASIA.<sup>6,7</sup>

## Clinical Manifestations

The clinical manifestations of Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) in the context of breast implants are diverse, multifactorial, and often nonspecific. Patients affected by ASIA following the placement of silicone breast implants may present with a wide spectrum of symptoms that overlap with those of other autoimmune and inflammatory conditions, making diagnosis a significant challenge. Although the clinical presentation can vary considerably, a constellation of systemic symptoms has been consistently reported in affected individuals, including musculoskeletal, neurological, dermatological, and constitutional complaints. Collectively, these symptoms are now commonly referred to as "Breast Implant Illness" (BII), which represents a subset within the broader ASIA spectrum.<sup>7,8</sup>

## Constitutional Symptoms

One of the hallmark features of ASIA related to breast implants is the presence of chronic, debilitating fatigue. Patients frequently report persistent exhaustion that is not relieved by rest and significantly impairs their daily activities. This fatigue often resembles that seen in conditions such as chronic fatigue syndrome (CFS) or fibromyalgia and may coexist with other nonspecific constitutional symptoms, including low-grade fever, weight loss, and night sweats. These constitutional manifestations, although nonspecific, are highly prevalent among patients with ASIA and often contribute to the overall sense of malaise and illness.<sup>7,8</sup>

## Musculoskeletal Symptoms

Musculoskeletal involvement is a prominent feature of ASIA in breast implant recipients. Patients often experience diffuse myalgia and arthralgia, which may mimic other autoimmune disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, or polymyalgia rheumatica. The pain may affect multiple joints and muscle groups and is typically described as migratory, worsening with physical activity, and associated with morning stiffness. Some individuals may also present with overt signs of inflammatory arthritis, characterized by swelling, warmth, and tenderness in the affected joints, although radiographic evidence of joint erosion is usually absent. Myositis or polymyositis has also been reported in more severe cases, manifesting as proximal muscle weakness and elevated serum creatine kinase levels.<sup>7,8</sup>

## Neurological Symptoms

A wide range of neurological symptoms has been documented in patients with ASIA following breast implant placement. These may include cognitive dysfunction, commonly referred to as "brain fog," which is characterized by impaired memory, difficulty concentrating, and slowed cognitive processing. Neurological manifestations may also extend to peripheral neuropathy, with patients reporting paresthesia, numbness, and tingling sensations in the extremities. Additionally, headaches, dizziness, and episodes of lightheadedness are common complaints. In rare cases, more severe neurological sequelae, such as seizures or demyelinating disorders like multiple sclerosis, have been suggested as potential complications, although the causal relationship between silicone breast implants and these conditions remains a subject of debate.<sup>7,8</sup>

## Dermatological Symptoms

Cutaneous manifestations are frequently observed in ASIA related to breast implants. Patients may develop a range of dermatological symptoms, including nonspecific rashes, pruritus, and erythema. These skin changes may occur in the absence of any local infection or capsular contracture around the implant. In some instances, individuals with a predisposition to autoimmune diseases may develop specific cutaneous lesions, such as photosensitivity or discoid lupus erythematosus-like eruptions. The skin manifestations in ASIA are often chronic and may fluctuate in severity over time.<sup>7,8</sup>

## Respiratory Symptoms

Some patients with ASIA associated with breast implants report respiratory symptoms, including shortness of breath, dyspnea on exertion, and chronic nonproductive cough. These symptoms may suggest an underlying inflammatory process affecting the lungs or pleura, although objective findings such as pulmonary function tests or chest imaging are frequently normal. In rare cases, interstitial lung disease has been described in association with silicone breast implants, raising concerns about the potential systemic distribution of silicone particles and their impact on the respiratory system. However, the exact pathophysiological mechanisms linking silicone to respiratory involvement remain poorly understood.<sup>7,8</sup>

## Gastrointestinal Symptoms

Gastrointestinal disturbances, including abdominal pain, bloating, nausea, and altered bowel habits, are commonly reported by patients with ASIA. These symptoms are nonspecific and may resemble irritable bowel syndrome (IBS) or functional dyspepsia. While gastrointestinal symptoms are not a defining feature of ASIA, their presence may reflect the broader systemic inflammation and immune dysregulation associated with the syndrome. Additionally, food intolerances and sensitivities, particularly to gluten and dairy products, have been anecdotally reported by patients

# Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

with ASIA following breast implant placement, although the mechanisms underlying these associations remain speculative.<sup>7,8</sup>

## Autoimmune and Inflammatory Features

A key characteristic of ASIA is its ability to trigger or exacerbate preexisting autoimmune conditions. Patients with a history of autoimmune disease may experience a worsening of their symptoms following breast implant placement, while others may develop new-onset autoimmune diseases such as systemic lupus erythematosus (SLE), Sjögren's syndrome, or Hashimoto's thyroiditis. Laboratory findings in such patients often reveal the presence of autoantibodies, such as antinuclear antibodies (ANA), rheumatoid factor (RF), or anti-thyroid peroxidase (anti-TPO) antibodies. Elevated inflammatory markers, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), may also be observed, although these findings are nonspecific and do not definitively confirm the diagnosis of ASIA.<sup>7,8</sup>

## Local Symptoms

Although ASIA is primarily a systemic syndrome, local symptoms related to the breast implants themselves may also be present. Capsular contracture, characterized by the formation of a thick fibrous capsule around the implant, is a common complication in patients with silicone breast implants and may be associated with pain, discomfort, and aesthetic deformity. In cases of implant rupture or silicone leakage, patients may develop granulomatous inflammation or silicone-induced lymphadenopathy. These local complications can contribute to the overall symptom burden and may exacerbate the systemic manifestations of ASIA.<sup>7,8</sup>

## Temporal Relationship and Symptom Evolution

One of the challenges in diagnosing ASIA in patients with breast implants is the variable temporal relationship between implant placement and the onset of symptoms. While some individuals develop symptoms shortly after implantation, others may remain asymptomatic for years before presenting with a full-blown clinical picture of ASIA. This delayed onset suggests that the immune system may take time to react to the adjuvant properties of silicone, potentially triggered by additional factors such as infections, trauma, or hormonal changes. Once initiated, the symptoms of ASIA tend to be chronic and may progressively worsen over time, particularly if the implants remain in place.<sup>7,8</sup>

The clinical manifestations of ASIA related to breast implants are protean and often overlap with other autoimmune and inflammatory conditions. Patients may present with a combination of constitutional, musculoskeletal, neurological, dermatological, respiratory, and gastrointestinal symptoms, along with laboratory evidence of immune dysregulation. The nonspecific nature of these symptoms makes early recognition challenging, underscoring the importance of maintaining a high index of suspicion in patients with breast implants who develop systemic complaints. Timely diagnosis

and intervention, including explantation and immune-modulating therapies, are critical to improving patient outcomes.<sup>7,8</sup>

## Diagnostic Methods

Diagnosing Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) in the context of breast implants is particularly challenging due to the nonspecific nature of its clinical manifestations and the overlap with other autoimmune, inflammatory, and chronic fatigue syndromes. Moreover, ASIA lacks standardized diagnostic criteria specific to breast implant-related cases, making the diagnostic process a multifaceted approach that combines clinical suspicion, patient history, physical examination, laboratory testing, and, in certain cases, imaging studies and biopsy. Here, we will discuss the various diagnostic methods used to identify ASIA in patients with breast implants, emphasizing the importance of a comprehensive and systematic approach.<sup>9,10</sup>

## Clinical Evaluation and Patient History

The cornerstone of diagnosing ASIA related to breast implants lies in a thorough clinical evaluation. Detailed patient history plays a pivotal role, as it is essential to identify the temporal relationship between the onset of symptoms and breast implant placement. Symptoms may begin months or even years after the initial implant surgery, which can make linking them to the implants difficult. Additionally, it is important to inquire about any prior or concurrent autoimmune or inflammatory disorders, as well as personal or family history of such conditions, which may predispose patients to ASIA.<sup>9,10</sup>

The constellation of symptoms reported by the patient, including fatigue, myalgia, arthralgia, cognitive dysfunction, skin manifestations, and others, should raise suspicion of ASIA, particularly if these symptoms cannot be explained by other medical conditions. A comprehensive review of systems should be conducted to evaluate the multisystemic nature of the illness. It is also crucial to investigate any local signs related to the breast implants, such as pain, capsular contracture, or changes in breast appearance, which may indicate local inflammatory processes or implant complications that could be contributing to systemic symptoms.<sup>9,10</sup>

## Physical Examination

Physical examination is an essential component of the diagnostic process, though its findings in ASIA are often nonspecific. Depending on the organ systems affected, patients may present with signs of systemic inflammation, such as swollen and tender joints, muscle tenderness, skin rashes, or lymphadenopathy. The breast and surrounding tissues should be thoroughly examined for any signs of capsular contracture, local inflammation, or implant rupture. Neurological examination may reveal sensory deficits, paresthesia, or motor weakness, particularly in cases where

## Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

peripheral neuropathy is present. While physical examination alone is insufficient to confirm the diagnosis of ASIA, it helps guide further diagnostic testing and helps rule out other potential causes of the patient's symptoms.<sup>9,10</sup>

### Laboratory Testing

Laboratory investigations are a critical component in the diagnosis of ASIA, as they provide objective evidence of immune dysregulation and inflammation. However, it is important to note that there is no single laboratory test that can definitively diagnose ASIA. Instead, a combination of tests is typically employed to assess the presence of systemic inflammation, autoimmunity, and organ dysfunction.<sup>9,10</sup>

- **Inflammatory Markers:** Serum inflammatory markers, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are often elevated in patients with ASIA, indicating the presence of systemic inflammation. However, these markers are nonspecific and can be elevated in a wide range of inflammatory and infectious conditions, making them supportive rather than diagnostic in ASIA.<sup>9,10</sup>
- **Autoantibodies:** The presence of autoantibodies is a key feature of ASIA, as it suggests the development of autoimmune responses triggered by the adjuvant properties of silicone. Common autoantibodies tested include antinuclear antibodies (ANA), rheumatoid factor (RF), and anti-thyroid peroxidase (anti-TPO) antibodies. ANA is frequently positive in patients with ASIA, though the titers and specific patterns may vary. ANA positivity in ASIA should be interpreted in conjunction with the clinical presentation and other laboratory findings, as it can also be present in other autoimmune conditions. Additionally, antibodies specific to other autoimmune diseases, such as anti-dsDNA (for systemic lupus erythematosus) or anti-SSA/SSB (for Sjögren's syndrome), may also be present in cases where the patient develops a distinct autoimmune condition in conjunction with ASIA.<sup>9,10</sup>
- **Immunoglobulin Levels and Complement:** Abnormalities in immunoglobulin levels, such as elevated IgG or IgM, may be seen in patients with ASIA. Similarly, complement levels, including C3 and C4, may be altered, reflecting ongoing immune activation. Hypocomplementemia can be observed in some cases, indicating complement consumption in the context of immune complex formation and deposition.<sup>9,10</sup>
- **Cytokine Profiling:** Emerging evidence suggests that patients with ASIA may have abnormal cytokine profiles, indicating immune system dysregulation. Elevations in pro-inflammatory cytokines such as IL-6, IL-1, TNF- $\alpha$ , and others

have been reported in small studies of ASIA. However, cytokine profiling is not yet a routine diagnostic tool and is typically limited to research settings.<sup>9,10</sup>

- **HLA Typing:** Genetic predisposition to autoimmune diseases is a factor in ASIA, and HLA typing may be useful in certain cases. Specific HLA alleles, such as HLA-DRB1 and HLA-DQB1, have been associated with an increased risk of developing ASIA. Although HLA typing is not widely used in clinical practice due to its cost and limited availability, it may help identify individuals who are genetically predisposed to developing autoimmune responses after exposure to adjuvants like silicone.<sup>9,10</sup>

### Imaging Studies

Imaging studies are often employed in the evaluation of ASIA, particularly to assess the integrity of the breast implants and to detect any local or systemic complications. The following imaging modalities may be useful:

- **Magnetic Resonance Imaging (MRI):** MRI is the gold standard for evaluating breast implant integrity. It is highly sensitive for detecting silicone implant rupture, which can be a trigger for systemic symptoms in ASIA. Silicone leakage or migration may lead to local inflammatory reactions, granuloma formation, and lymphadenopathy, all of which can contribute to systemic autoimmune responses. MRI can also assess capsular contracture, which is another common local complication of silicone breast implants that may exacerbate ASIA symptoms.<sup>9,10</sup>
- **Ultrasound:** Breast ultrasound is a less invasive and more accessible imaging modality compared to MRI. It is often used as a first-line tool for evaluating breast implants, particularly in cases where there is suspicion of rupture or local inflammation. While not as sensitive as MRI for detecting silent implant ruptures, ultrasound can identify large silicone extravasations and guide further diagnostic testing.<sup>9,10</sup>
- **Positron Emission Tomography (PET)/CT Scan:** PET/CT scans can be useful in identifying systemic inflammatory and autoimmune activity in patients with ASIA. These scans can detect increased metabolic activity in inflamed tissues, such as lymph nodes, muscles, or other affected organs, suggesting the presence of systemic inflammation. However, PET/CT is not routinely used for diagnosing ASIA and is typically reserved for cases where malignancy or other systemic processes are suspected.<sup>9,10</sup>

# Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

## Histopathological Examination and Biopsy

In selected cases, particularly when there is concern for implant rupture or local silicone-related inflammation, histopathological examination of tissue biopsies may be warranted. This is especially important in cases where silicone-induced lymphadenopathy, granuloma formation, or capsular contracture is suspected. Biopsy of the implant capsule or surrounding tissues can reveal chronic inflammation, fibrosis, or granulomatous inflammation, all of which are consistent with the local effects of silicone. Additionally, if lymph nodes are enlarged or suspicious on imaging, biopsy may help rule out malignancy and confirm silicone-induced lymphadenopathy.<sup>9,10</sup>

## Diagnostic Criteria for ASIA

In 2011, Shoenfeld and Agmon-Levin proposed diagnostic criteria for ASIA, which have since been adapted for use in breast implant-related cases. The criteria include major and minor criteria, and a diagnosis of ASIA can be made if the patient meets at least two major criteria or one major and two minor criteria. The major criteria include exposure to an adjuvant (such as silicone breast implants), the development of specific manifestations (e.g., fatigue, arthralgia, cognitive impairment), and improvement of symptoms following removal of the adjuvant. Minor criteria include the presence of autoantibodies, HLA predisposition, and previous exposure to adjuvants.<sup>9,10</sup>

The diagnosis of ASIA related to breast implants requires a comprehensive and multifactorial approach that incorporates clinical evaluation, laboratory testing, imaging studies, and, in select cases, histopathological analysis. While the lack of a single definitive diagnostic test makes diagnosing ASIA challenging, a combination of methods tailored to the individual patient's clinical presentation can help identify the syndrome and guide appropriate management.<sup>9,10</sup>

## Treatment

The management of Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) in patients with breast implants is multifaceted and requires a personalized approach. Given the heterogeneous nature of ASIA and the broad spectrum of clinical manifestations, treatment is often guided by the severity of symptoms, the presence of comorbid autoimmune conditions, and the patient's overall health status. While the central focus of therapy is typically the removal of the causative adjuvant—silicone breast implants—other treatment strategies involve the modulation of immune responses, symptom relief, and management of any associated autoimmune diseases. The primary goals of treatment are to reduce systemic inflammation, halt the progression of immune-mediated damage, and improve the patient's quality of life.<sup>11,12</sup>

## Explantation Surgery

The cornerstone of treatment for ASIA related to breast implants is the surgical removal of the implants, often

referred to as **explantation**. This procedure may also include **capsulectomy**, the removal of the fibrous capsule surrounding the implant, particularly in cases where capsular contracture or local inflammation is evident. Explantation is based on the premise that the removal of the offending adjuvant (silicone) can alleviate the immune response and lead to an improvement in systemic symptoms. Many studies and case reports have demonstrated that patients experience significant improvement or even complete resolution of their symptoms after explantation. However, the extent of recovery can vary, and some patients may continue to experience residual symptoms or develop new autoimmune conditions even after implant removal.<sup>11,12</sup>

- **Complete versus Partial Capsulectomy:** The decision to perform a complete capsulectomy, where the entire fibrous capsule is removed, or a partial capsulectomy, where only a portion is excised, is a critical factor in the surgical management of ASIA. A complete capsulectomy is generally favored in cases where there is significant capsular contracture, chronic inflammation, or evidence of silicone leakage. This approach aims to reduce the immune system's exposure to residual silicone particles and mitigate the ongoing inflammatory response. However, a complete capsulectomy may be technically challenging and carries a higher risk of surgical complications. In cases where there is no evidence of capsular contracture or implant rupture, a partial capsulectomy may suffice.<sup>11,12</sup>
- **Timing of Explantation:** The optimal timing of explantation surgery remains a topic of debate. While earlier intervention is generally associated with better outcomes, some patients may choose to delay surgery due to concerns about the aesthetic consequences or the risks of surgery. In cases where there is compelling clinical evidence of ASIA, such as the presence of autoimmune markers or severe systemic symptoms, early explantation is strongly recommended to prevent further immune-mediated damage.<sup>11,12</sup>
- **Post-explantation Outcomes:** Postoperative outcomes can vary among patients. Some individuals experience dramatic improvement in their systemic symptoms within weeks to months following surgery, while others may continue to suffer from persistent or relapsing symptoms. The variability in outcomes may be influenced by factors such as the duration of implant exposure, the presence of other autoimmune diseases, and individual genetic susceptibility. Studies suggest that patients who undergo explantation earlier in the course of their illness are more likely to experience complete resolution of symptoms.<sup>11,12</sup>

# Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

## Immunomodulatory Therapy

In addition to explantation, many patients with ASIA require **immunomodulatory therapy** to control ongoing inflammation and autoimmune responses. This is especially true in cases where explantation alone does not result in complete symptom resolution or in patients who have developed an associated autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or Sjögren's syndrome. Immunomodulatory treatments are aimed at reducing the hyperactive immune response and may include:

- **Corticosteroids:** Corticosteroids, such as prednisone, are frequently used as first-line therapy to control acute inflammatory symptoms in patients with ASIA. These agents are highly effective in reducing inflammation, alleviating symptoms such as joint pain, myalgia, and fatigue, and suppressing the immune response. However, the long-term use of corticosteroids is associated with significant side effects, including osteoporosis, weight gain, hyperglycemia, and increased risk of infections. Therefore, corticosteroids are typically reserved for short-term use during disease flares or in patients with severe symptoms.<sup>11,12</sup>
- **Disease-Modifying Antirheumatic Drugs (DMARDs):** In patients with more severe or chronic forms of ASIA, particularly those with an associated autoimmune disease, **DMARDs** may be necessary to achieve long-term disease control. Methotrexate, azathioprine, and hydroxychloroquine are commonly used DMARDs that can modulate immune function and reduce systemic inflammation. These agents are often used in combination with corticosteroids to allow for steroid tapering and minimize side effects. Close monitoring for potential drug toxicity, such as liver dysfunction or bone marrow suppression, is essential when using DMARDs.<sup>11,12</sup>
- **Biologic Agents:** For patients with refractory ASIA who do not respond adequately to traditional DMARDs, biologic agents may be considered. These therapies, which include **TNF inhibitors** (such as infliximab or adalimumab), **B-cell depleting agents** (such as rituximab), and **IL-6 inhibitors** (such as tocilizumab), target specific components of the immune system that drive the inflammatory process. Biologic agents have shown efficacy in treating autoimmune diseases such as RA, SLE, and Sjögren's syndrome, and may be beneficial in patients with ASIA who have overlapping autoimmune features. However, biologics are associated with a risk of serious infections and other adverse effects, and their use

must be carefully considered on a case-by-case basis.<sup>11,12</sup>

## Symptomatic Management

Symptomatic management is an integral component of the treatment plan for ASIA, particularly in patients with chronic symptoms that affect their quality of life. A multidisciplinary approach that addresses both physical and psychological symptoms is essential for comprehensive care.<sup>11,12</sup>

- **Pain Management:** Many patients with ASIA experience chronic pain, including myalgia, arthralgia, and neuropathic pain. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, are commonly used for pain relief, though their long-term use should be monitored due to potential gastrointestinal and cardiovascular side effects. In cases of neuropathic pain, medications such as gabapentin or pregabalin may be effective in reducing symptoms. Physical therapy may also be beneficial in managing musculoskeletal pain and improving functional outcomes.<sup>11,12</sup>
- **Fatigue Management:** Chronic fatigue is a debilitating symptom for many patients with ASIA, and managing this symptom often requires a multifaceted approach. In addition to addressing the underlying inflammation, strategies such as graded exercise programs, cognitive behavioral therapy (CBT), and energy conservation techniques may help improve fatigue levels. In cases where fatigue persists despite explantation and medical therapy, referral to a specialist in chronic fatigue or pain management may be warranted.<sup>11,12</sup>
- **Psychological Support:** The psychological impact of ASIA and breast implant illness should not be underestimated. Many patients experience anxiety, depression, and emotional distress related to their illness and the uncertainty surrounding their prognosis. Referral to a mental health professional, such as a psychologist or psychiatrist, for counseling or cognitive-behavioral therapy can be beneficial in helping patients cope with the emotional burden of their condition. Support groups for individuals with ASIA or breast implant illness may also provide a valuable source of social and emotional support.<sup>11,12</sup>

## Management of Associated Autoimmune Conditions

A significant subset of patients with ASIA develop concomitant autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, or Sjögren's syndrome. These conditions require targeted treatment based on their specific pathophysiology, and their management may overlap with the immunomodulatory therapies discussed above. For example, patients with lupus may benefit from the use of antimalarial drugs such as hydroxychloroquine, while those with RA may require methotrexate or TNF inhibitors. In

## Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

patients with multiple autoimmune conditions, a tailored treatment approach that addresses the specific features of each condition is critical for optimal disease management.<sup>11,12</sup>

### Monitoring and Follow-up

Regular monitoring and follow-up are essential components of the long-term management of ASIA. Patients should be closely monitored for the recurrence of symptoms or the development of new autoimmune diseases following explantation. Laboratory testing, including inflammatory markers and autoantibody profiles, may be used to assess disease activity and guide adjustments in immunosuppressive therapy. In cases where patients remain on long-term DMARDs or biologic agents, routine monitoring for drug-related toxicities is also necessary. Regular follow-up with a multidisciplinary team, including rheumatologists, immunologists, and plastic surgeons, ensures that patients receive comprehensive care that addresses all aspects of their illness.<sup>11,12</sup>

### Emerging Therapies and Future Directions

Research into the pathophysiology of ASIA and breast implant illness is ongoing, and new treatment modalities may emerge as our understanding of the condition evolves. Novel therapies targeting specific immune pathways implicated in ASIA, such as cytokine inhibitors or immune checkpoint modulators, may offer promising new avenues for treatment. Additionally, ongoing studies into the long-term outcomes of explantation and the role of genetic factors in ASIA may help refine diagnostic criteria and improve therapeutic strategies in the future.<sup>11,12</sup>

In conclusion, the treatment of ASIA related to breast implants is a complex and evolving field that requires a multifaceted approach. Explantation surgery remains the cornerstone of therapy, but many patients also require immunomodulatory treatments and symptomatic management to achieve optimal outcomes. A personalized treatment plan that addresses both the systemic and local manifestations of ASIA, as well as the patient's individual health status, is critical to improving patient quality of life and preventing long-term complications.<sup>11,12</sup>

### CONCLUSION

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), specifically in the context of breast implants, represents a complex and multifaceted clinical entity that challenges our understanding of immunology, surgery, and patient care. The syndrome, characterized by a wide spectrum of nonspecific and often debilitating systemic symptoms, has been increasingly recognized in patients with silicone breast implants. It underscores the potential for adjuvants, such as silicone, to trigger aberrant immune responses, leading to chronic inflammation, autoimmune phenomena, and a

constellation of symptoms that can significantly impact a patient's quality of life.

The pathophysiology of ASIA in breast implant patients remains incompletely understood, with current evidence pointing to a combination of genetic predisposition, immune system dysregulation, and environmental factors. Silicone, once believed to be inert, can act as a potent adjuvant, stimulating both innate and adaptive immune responses. The chronic exposure to these immune stimuli may lead to a breakdown in immune tolerance, manifesting in conditions ranging from chronic fatigue and myalgia to more severe autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, or Sjögren's syndrome.

Diagnosis of ASIA remains a significant clinical challenge due to its nonspecific presentation and the overlap with other autoimmune and inflammatory disorders. The lack of standardized diagnostic criteria has led to a reliance on clinical judgment, patient history, and the exclusion of other potential causes. Imaging studies and laboratory evaluations, while supportive, are often inconclusive, making the diagnosis of ASIA heavily reliant on a comprehensive understanding of the patient's clinical course and symptomatology. This diagnostic uncertainty highlights the need for more specific biomarkers and consensus guidelines to facilitate early recognition and intervention.

In terms of management, explantation surgery remains the cornerstone of treatment for ASIA related to breast implants. Numerous case studies have demonstrated symptomatic relief and, in some instances, complete resolution of symptoms following the removal of silicone implants, with or without associated capsulectomy. However, it is important to recognize that the success of explantation varies, and not all patients experience full recovery. Some may continue to suffer from residual symptoms or develop further autoimmune complications, which necessitates a multidisciplinary approach involving immunologists, rheumatologists, and plastic surgeons.

Immunomodulatory therapies, including corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics, play an essential role in the management of patients who do not achieve complete symptom resolution post-explantation or who present with coexisting autoimmune conditions. These therapies aim to control systemic inflammation, alleviate immune-mediated tissue damage, and improve the patient's functional capacity. However, the long-term use of immunosuppressive agents carries risks, including heightened susceptibility to infections and drug-related toxicities, necessitating vigilant monitoring and individualized treatment plans.

From a broader perspective, ASIA challenges the safety assumptions surrounding medical implants, particularly silicone-based devices. While breast implants are widely used and remain an important option for both cosmetic and reconstructive surgery, their potential to induce autoimmune



## Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Related to Breast Implants: A Comprehensive Review

and inflammatory responses warrants ongoing scrutiny. Future research should aim to delineate the mechanisms by which silicone acts as an adjuvant, identify genetic and immunologic risk factors for developing ASIA, and refine diagnostic criteria to aid clinicians in early detection. Moreover, long-term cohort studies are needed to track patient outcomes following explantation and assess the efficacy of various therapeutic interventions.

The psychosocial impact of ASIA should not be overlooked. Many patients experience significant emotional distress, anxiety, and depression related to their illness and the decision-making process surrounding explantation. These patients often require not only medical and surgical interventions but also psychological support to cope with the uncertainty and potential chronicity of their symptoms. Comprehensive care that includes mental health resources, patient education, and support groups is critical to improving overall outcomes and quality of life for individuals affected by ASIA.

In conclusion, ASIA syndrome in the context of breast implants represents an evolving clinical phenomenon with profound implications for both patients and healthcare providers. While significant progress has been made in understanding the immunologic mechanisms underlying the syndrome and developing treatment strategies, many questions remain unanswered. Moving forward, the medical community must continue to explore the intricate relationship between adjuvants and immune activation, develop standardized protocols for diagnosis and management, and emphasize a patient-centered approach to care. Through interdisciplinary collaboration, further research, and patient advocacy, the future holds the promise of more effective treatments and better outcomes for those affected by this challenging and often misunderstood syndrome.

### REFERENCES

- I. Shoenfeld Y, Agmon-Levin N. ASIA; Autoimmune/inflammatory syndrome induced by adjuvant. *J Autoimmun.* 2011;36:4–8.
- II. Andreoli L, Tincani L. Undifferentiated connective tissue disease, fibromyalgia and the environmental actors. *Curr Opin Rheumatol.* 2017;29:355–60.
- III. Alijotas-Reig J, Esteve Valverde E, Gil-Aliberas N, García-Giménez V. Autoimmune/inflammatory syndrome induced by adjuvants - ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature. *Immunol Res.* 2018;66:120–40.
- IV. Cala-Urbe L, Navarro-Escobar A, León JC, Buitrago-García D, Teherán A. Características de individuos sometidos a infiltración de materiales extra nos con fines estéticos sobre los que se realizó investigación judicial en Colombia. *Cir Plast Iberolatinoam.* 2017;43:137–42.
- VI. Vera-Lastra O, Medina G, Cruz-Domínguez MdelP, Ramírez P, Gayosso-Rivera JA, Anduaga-Domínguez H, et al. Human adjuvant disease induced by foreign substance: A new model of ASIA (Shoenfeld's syndrome). *Lupus.* 2012;21:128–30.
- VII. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016, American College of Rheumatology/European League Against Rheumatism
- VIII. classifications criteria for primary Sjögren syndrome: A consensus and data - driven methodology involving three international patient cohorts. *Ann Rheum Dis.* 2017;76:9–16.
- IX. Wolfe F, Clauw D, Fitzcharles MA, Goldenberg D, Katz RS, Mease P, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. *Arthritis Care Res.* 2010;62:600–10.
- X. Dagan A, Kogan M, Shoenfeld Y, Segal G. When uncommon and common coalesce: Adult onset Still's disease associated with breast augmentation as part of autoimmune syndrome induced by adjuvants (ASIA). *Clin Rheumatol.* 2016;35:1643–8.
- XI. Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants: Where have we come from? Where are we going? A proposal for new diagnostic criteria. *Lupus.* 2015;24:1012–8.
- XII. Watad A, Qureshi M, Bragazzi NL, Cervera R, Cohen Tervaert JW, Amital H, et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: Descriptive analysis of 300 patients from the international ASIA syndrome registry. *Clin Rheumatol.* 2018;37:483–93.
- XIII. Ameratunga R, Gillis D, Gold M, Linneberg A, Elwood JM. Evidence refuting the existence of
- XIV. Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA). *J Allergy Clin Immunol Pract.* 2017;5:1551–5.
- XV. Jara LJ, García-Collinot G, Medina G, Cruz Domínguez MP, Vera-Lastra O, Carranza-Muleiro RA, et al. Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome). *Immunol Res.* 2017;65:8–16.